Second chance: new combo may rescue failed stem cell transplants
NCT ID NCT02161783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of chemotherapy drugs (fludarabine and cyclophosphamide) plus low-dose radiation to prepare the body for a second stem cell transplant in people whose first transplant failed. The goal is to get the new donor cells to grow and start making blood cells by day 42. The trial enrolls 50 patients with primary or secondary graft failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fludarabine, Cyclophosphamide, Total Body Irradiation, and Hematopoietic stem cell infusion
- What this could lead to
- If successful, this could provide a reliable rescue treatment for patients whose stem cell transplant fails, helping their new immune system take hold.
- What could go wrong
- This is a small, early-phase study (50 people) and the regimen carries risks like infection, graft-versus-host disease, and organ damage. Success is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY GRAFT FAILURE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota Medical Center, Fairview
RECRUITINGMinneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.